BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc (NASDAQ: BCRX) is a biotechnology company focused on developing treatments for hereditary angioedema (HAE) and other rare diseases. Its primary commercial product is ORLADEYO, an oral therapy for preventing HAE attacks, along with RAPIVAB, an injectable treatment for acute influenza in the United States, with additional peramivir-based products marketed internationally.  

According to our previous US Daily Report published on 'BCRX' on March 31, 2026, Kalkine provided a ‘Speculative Buy’ stance on the stock at USD 9.45 based on fundamental analysis and the stock price has now moved up by 3.07% and trading below resistance 1.

Noted below are the details of technical summary provided in our previous report:

BCRX’s Daily Chart

BCRX's shares are currently trading higher; however, trading volumes are declining. This divergence suggests that the bullish momentum may be fading, indicating a possible near-term decline in the stock price. Considering the current trading environment and associated risks, a ‘Sell’ rating is assigned to BCRX at the current market price of USD 9.74 as of April 10, 2026 (6:50 am PDT). 

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 10, 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.